Moogene Medi Co., Ltd. (XKON:322970)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,165.00
+40.00 (1.88%)
At close: Mar 5, 2026
Market Cap20.15B -15.4%
Revenue (ttm)12.95M -87.2%
Net Income-2.08B
EPS-332.00
Shares Out10.05M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,622
Average Volume5,304
Open2,125.00
Previous Close2,125.00
Day's Range2,000.00 - 2,175.00
52-Week Range1,720.00 - 2,440.00
Beta-0.03
RSI48.55
Earnings Daten/a

About Moogene Medi

Moogene Medi Co., Ltd. develops nanobiotechnology-based drug delivery systems. It develops lipid nanoparticle (LNP) materials for pharmaceutical protein delivery; RNP (sgRNA+ CRISPR Cas9)-encapsulated LNP for gene therapy; novel therapy for colorectal or pancreatic cancer with anticancer drug resistance due to genetic mutation by using RNP-encapsulated LNP; and topical treatment for androgenic alopecia therapy. The company was founded in 2016 and is headquartered in Hanam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 322970
Full Company Profile

Financial Performance

In 2019, Moogene Medi's revenue was 12.95 million, a decrease of -87.17% compared to the previous year's 100.95 million. Losses were -2.08 billion, 41.4% more than in 2018.

Financial Statements